Pfizer to Cut U.S. Sales Force by 20%
Pfizer said Tuesday it will trim its U.S. sales force by 20% as part of an ongoing review process announced in October.
Pfizer said it will provide more details, including a long-term outlook and additional reorganization moves, in January.
'Consistent with Pfizer's long-standing values, we will provide affected employees with support services and benefits during their transitions,' Ian Read, president of Pfizer worldwide pharmaceutical operations, said in a statement. 'We will continue to support and reward our top performers.'
The company said it will maintain strong support for products including Lipitor, Celebrex, Geodon, Lyrica, Exubera, Chantix and Sutent.